Clinical Trials Browser

Has results × Breast Neoplasms × Dasatinib × Clear all

NCT01471106 2024-07-10

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Phase 2 Completed

26 enrolled 10 charts

Breast Neoplasms

NCT01306942 2023-03-30

Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients

Phase 1/2 Completed

37 enrolled 30 charts

Breast Neoplasms

NCT02720185 2022-06-03

Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR

Phase 2 Terminated

5 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00566618 2022-02-25

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1/2 Completed

31 enrolled 8 charts

Breast Neoplasms

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2 Terminated

97 enrolled 7 charts

Breast Neoplasms

NCT00820170 2019-08-13

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Phase 1/2 Completed

55 enrolled 19 charts

Breast Neoplasms, Neoplasms

NCT00410813 2017-07-02

S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Phase 2 Completed

85 enrolled 18 charts

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT00696072 2016-06-13

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Phase 2 Completed

120 enrolled 13 charts

Breast Neoplasms

NCT00903006 2015-02-02

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Phase 1/2 Terminated

11 enrolled 6 charts

Breast Neoplasms

NCT00924352 2014-10-13

Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Phase 1/2 Completed

56 enrolled 14 charts

Breast Neoplasms

NCT00546104 2013-07-17

Phase II Dasatinib Study in Advanced Breast Cancer

Phase 2 Completed

31 enrolled 10 charts

Breast Neoplasms

NCT00767520 2013-02-28

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Phase 2 Completed

155 enrolled 19 charts

Breast Neoplasms

NCT00817531 2012-08-31

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

Phase 2 Terminated

22 enrolled 7 charts

Breast Neoplasms

NCT00371345 2011-04-26

Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer

Phase 2 Completed

92 enrolled 27 charts

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT00371254 2011-03-15

A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Phase 2 Completed

55 enrolled 28 charts

Breast Neoplasms, Neoplasm Metastasis, Recurrence